Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Drugs Made In America Acquisition (DMAA) Operating Expenses (2025)

Drugs Made In America Acquisition filings provide 1 years of Operating Expenses readings, the most recent being $2.1 million for Q4 2025.

  • Quarterly Operating Expenses changed N/A to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Dec 2025, changed N/A year-over-year, with the annual reading at $2.8 million for FY2025, 906.28% up from the prior year.
  • Operating Expenses hit $2.1 million in Q4 2025 for Drugs Made In America Acquisition, up from $263703.0 in the prior quarter.
  • Across five years, Operating Expenses topped out at $2.1 million in Q4 2025 and bottomed at $131919.0 in Q2 2025.